Hardman John, Liu ZiWei, Brady Grainne, Roe Justin, Kerawala Cyrus, Riva Francesco, Clarke Peter, Kim Dae, Bhide Shreerang, Nutting Christopher, Harrington Kevin, Paleri Vinidh
Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Institute of Cancer Research, London, UK.
Head Neck. 2020 May;42(5):1089-1104. doi: 10.1002/hed.26100. Epub 2020 Feb 18.
Transoral robotic surgery (TORS) for recurrent head and neck (H&N) cancer is an emerging but relatively infrequent procedure.
Systematic review and meta-analysis of studies reporting survival data and functional outcomes for patients undergoing TORS for previously treated H&N cancers.
Eight hundred seventy-eight records were identified, of which eight were eligible for inclusion, covering 161 cases (range 1-64). The pooled rates were as follows: 2-year overall survival 73.8% (4 studies, range 70.6-75.0, 95% confidence intervals (CI) 65.4 to 81.5, [I 0.0%, P = 1.0]); 2-year disease-free survival 74.8% (4 studies, range 56.2-92.0, 95% CI 63.3 to 84.8, [I 36.9%, P = .2]); postoperative hemorrhage 9.3% (4 studies, range 3.3-13.3, 95% CI 4.7 to 15.1, [I 0.0%, P = .5]).
Functional and oncological outcomes are favorable, although the follow-up is limited in the literature. Larger cohorts with longer follow-up are needed for definitive conclusions to be drawn.
经口机器人手术（TORS）用于复发性头颈部（H&N）癌是一种新兴但相对不常见的手术。
对报告接受TORS治疗既往治疗过的H&N癌患者生存数据和功能结局的研究进行系统评价和荟萃分析。
共识别出878条记录，其中8条符合纳入标准，涵盖161例患者（范围1 - 64例）。汇总率如下：2年总生存率73.8%（4项研究，范围70.6 - 75.0，95%置信区间（CI）65.4至81.5，[I² 0.0%，P = 1.0]）；2年无病生存率74.8%（4项研究，范围56.2 - 92.0，95% CI 63.3至84.8，[I² 36.9%，P = 0.2]）；术后出血率9.3%（4项研究，范围3.3 - 13.3，95% CI 4.7至15.1，[I² 0.0%，P = 0.5]）。
尽管文献中的随访有限，但功能和肿瘤学结局良好。需要更大规模队列和更长时间的随访才能得出明确结论。
